Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Rakovina Therapeutics Inc. V.RKV

Rakovina Therapeutics Inc is engaged in drug discovery research, preclinical and clinical development, and regulatory affairs necessary to advance breakthrough innovations to become potential life-changing treatments in the oncology field. Its oncology pipeline has the potential to deliver biomarker-driven treatments for patients across multiple tumor types. Some f its products in the pipeline include kt-2000 Next Generation PARP-inhibitors, kt-3000 Dual Action DDR-inhibitors, and kt-4000 DNA...

The Market Herald Price Sensitive
{{currentVideo.title}} {{currentVideo.relativeTime}}
{{currentVideo.storiesTitle}}:
{{story.companySymbol}}
{{story.companySymbol}} {{story.headline}}
< Previous bulletin
Next bulletin >
View modes: 

RE:2021 Financial Results/Provides Corporate Update TSXV:RKV

https://www.rakovinatherapeutics.com/  rate and reply

2021 Financial Results/Provides Corporate Update TSXV:RKV

VANCOUVER, British Columbia, April 27, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based on...read more

Rakovina Therapeutics Presents Preclinical Data Supporting

VANCOUVER, British Columbia, April 12, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company committed to advancing new cancer therapies based...read more

InvestmentPitch Media Video

Vancouver, British Columbia--(Newsfile Corp. - November 17, 2021) - Rakovina Therapeutics Inc. (TSXV: RKV), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA...read more

The Power Play by The Market Herald Releases New Interviews

Rakovina (RKV) is partnering with St. Baldrick's Foundation to develop treatments for childhood bone cancer. It was selected to join a three-year C$1,297,000 research program funded by St...read more